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ABSTRACT
Although the role of acyl-CoA synthetase 4 (ACSL4) in mediating an aggressive 
phenotype is well accepted, there is little evidence as to the early steps through which 
ACSL4 increases tumor growth and progression. In this study, and by means of the stable 
transfection of MCF-7 cells with ACSL4 using the tetracycline Tet-Off system (MCF-7 Tet-
Off/ACSL4), we identify the mTOR pathway as one of the main specific signatures of 
ACSL4 expression and demonstrate the partial involvement of the lipoxygenase pathway 
in the activation of mTOR. The specificity of ACSL4 action on mTOR signaling is also 
determined by doxycycline inhibition of ACSL4 expression in MCF-7 Tet-Off/ACSL4 cells, 
by the expression of ACSL4 in the non-aggressive T47D breast cancer cell line and by 
knocking down this enzyme expression in the MDA-MB-231 breast cancer cells, which 
constitutively express ACSL4. ACSL4 regulates components of the two complexes of the 
mTOR pathway (mTORC1/2), along with upstream regulators and substrates.
We show that mTOR inhibitor rapamycin and ACSL4 inhibitor rosiglitazone can 
act in combination to inhibit cell growth. In addition, we demonstrate a synergistic 
effect on cell growth inhibition by the combination of rosiglitazone and tamoxifen, an 
estrogen receptor α (ERα) inhibitor. Remarkably, this synergistic effect is also evident 
in the triple negative MDA-MB-231 cells in vitro and in vivo.
These results suggest that ACSL4 could be a target to restore tumor hormone 
dependence in tumors with poor prognosis for disease-free and overall survival, in 
which no effective specifically targeted therapy is readily available.
INTRODUCTION
Cancer is a disease with genomic perturbation 
leading to dysregulation of multiple pathways within the 
cellular system. Oncogenic selection functions at the level 
of networks of gene expression and signaling pathways, 
while a body of data accumulated in the past years 
indicates that the metabolism of arachidonic acid (AA) is 
involved in the maintenance of survival and proliferating 
capacities of various types of normal and cancer cells and 
thus plays a role in tumor progression [1–3].
The expression of acyl-CoA synthetase 4 (ACSL4), 
an enzyme working in AA metabolism, has been shown 
to be associated with aggressiveness of several types of 
cancer such as colon and hepatocellular carcinoma [4–10]. 
We and others have demonstrated a positive correlation 
of ACSL4 expression and aggressiveness in breast cancer 
cell lines, with the highest expression found in metastatic 
lines derived from triple negative (estrogen-receptor-α 
(ERα)-negative, progesterone-receptor (PR)-negative 
and not overexpressing human epidermal growth factor 
2 receptor (HER2) protein) tumor breast cancer (e.g. 
MDA-MB-231 and Hs578T) [6, 9].
Triple-negative breast cancer is a subtype that accounts 
for approximately 15% of breast cancer and is hence an 
important area of research for researchers and clinicians 
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alike, as it exhibits poor prognosis for disease-free and overall 
survival and no effective therapy is readily available.
Functionally, we and others have found that ACSL4 
is part of the mechanism responsible for increased breast 
cancer cell proliferation, invasion and migration, both in 
vitro and in vivo [4, 6, 9, 10]. The sole transfection of MCF-
7 cells, a model of non-aggressive breast cancer cells, with 
ACSL4 cDNA transforms them into a highly aggressive 
phenotype, and their injection into nude mice has resulted 
in the development of growing tumors with marked nuclear 
polymorphism, a high mitotic index and low expression 
of ER and PR [4]. In addition, targeting ACSL4 in cells 
and in tumors has indeed proven to reverse the loss of 
ER expression [4]. These results are in agreement with 
those showing that ACSL4 expression correlates with the 
absence of ER in samples from human breast tumor [9] 
and that the expression of ACSL4 negatively controls the 
expression of ER during tumor growth.
Genetic analysis of different tumors over the 
past years has allowed the characterization of distinct 
molecular pathways altered during the development and 
progression of this disease. The idea of personalized 
medicine and molecular profiling for prognostic tests has 
led to a plethora of studies in the past 10 years, in search 
for genetic determinants of metastatic breast cancer. Such 
studies have identified gene sets, or “signatures”, whose 
expression in primary tumors is associated with higher risk 
of metastasis and poor disease outcome for the patients. 
Therefore, the identification of altered pathways and new 
therapeutic targets is critical to improve the management 
of a significant proportion of cancer patients.
Although the role of ACSL4 in mediating an 
aggressive phenotype in breast cancer is well accepted, 
the mechanism involved in this effect has yet to be fully 
elucidated. For this reason, the goal of this work was 
to study the signaling pathways triggered by ACSL4 
overexpression which mediate cell phenotype change from 
mildly aggressive to highly aggressive in breast cancer cells.
Here, by means of cell models of ACSL4 
overexpression or underexpression in addition to a 
pharmacological approach, we identify the mTOR 
pathway as one of the main specific signatures of 
ACSL4 expression. ACSL4 regulates components of the 
two complexes of the mammalian target of rapamycin 
(mTOR) pathway (mTORC1/2), along with its upstream 
regulators and substrates. Our findings reveal a significant 
increase in the phosphorylation of ribosomal protein S6 
kinase 70kDa polypeptide 1 (p70S6K) on Thr389 and its 
substrates -the ribosomal protein S6-. An increase was also 
observed in the phosphorylation of Rictor (rapamycin-
insensitive companion of mTOR) on Thr1135, substrate 
of p70S6K and component of mTORC2 complex. In 
addition, an enhancement was detected in AKT (protein 
kinase B or PKB) phosphorylation on Ser473. Glycogen 
synthase kinase-3 alpha and beta (GSK3α and GSK3β) 
phosphorylation levels on Ser21/9 also increased in 
response to ACSL4 expression, which inhibited GSK3 
activity and therefore contributed to mTOR activation. 
In addition, we show here a synergistic effect in the 
inhibition of cell growth by a combination of ACSL4 and 
ER inhibitors. The combination was effective in inhibiting 
cell proliferation and tumor growth in a very aggressive 
triple negative breast cancer cell line, MDA-MB-231, 
which does not express ER and overexpresses ACSL4. 
These results suggest that ACSL4, in combination with 
ER inhibitors, could be an interesting target to be used in 
combination with other inhibitors and which might prevent 
the side effects of supra-maximal doses and generate more 
positive effects than single-drug therapy.
RESULTS
An ACSL4 functional proteomic signature  
of MCF-7 Tet-Off/ACSL4 cells
Despite evidence linking the action of ACSL4 to the 
development of various types of cancer including colon, 
hepatocellular carcinoma, prostate and breast cancer, 
very little is known regarding the signal transduction 
mechanism by which ACSL4 influences these lesions.
In order to study the signaling pathways triggered 
by ACSL4, we first defined a functional protein signature 
of the ACSL4 pathway by using the reverse phase protein 
array (RPPA), a high-throughput antibody-based technique 
developed for functional proteomic studies to measure 
phosphorylation states, as well as total levels of key signaling 
pathway intermediaries. The analysis was performed on 
lysates derived from MCF-7 cells stably transfected with 
ACSL4 using the tetracycline Tet-Off system (MCF-7 Tet-
Off/ACSL4), MCF-7 Tet-Off empty vector and doxycycline-
treated MCF-7 Tet-Off/ACSL4 cells, the latter used to 
specifically override ACSL4 expression. The pattern of 
protein expression and/or phosphorylation was remarkably 
different between MCF-7 Tet-Off/ACSL4 and MCF-7 Tet-
Off empty vector (Figure 1).
A functional annotation analysis using the 
bioinformatic program DAVID [11] on the basis of RPPA 
data is shown in Table 1. This analysis revealed that 
mTOR signaling pathway was the second lowest p-value. 
Together with insulin and ERbB signaling and cancer, 
they were the top four signaling pathways with the lowest 
p-values. Pathways in cancer found included prostate 
cancer, chronic and acute myeloid leukemia, pancreatic, 
and colorectal cancer, glioma, melanoma, endometrial and 
non small cell lung cancer. The p53 signaling pathway was 
also included.
RPPA data showed that ACSL4 expression enhanced 
the phosphorylation of mTOR on Ser2448 without changes 
in its protein levels. mTOR has emerged as a critical 
effector in cell signaling pathways commonly dysregulated 
in human cancer. mTOR is regulated by growth factors and 
nutrients, which indicates that it is at the interface of two 
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different growth signals [12], and comprises a rapamycin- 
and nutrient-sensitive multiprotein complex (mTORC1) 
and a growth factor-sensitive nutrient-insensitive complex 
(mTORC2). mTORC1 modulates at least two separate 
downstream pathways that are conjectured to control the 
translation of a specific subset of mRNAs [13, 14]. ACSL4 
expression enhanced the phosphorylation of p70S6K on 
Thr389, a downstream target of mTORC1, and its substrate, 
S6 protein on Ser235/236 and 240/244 (Figure 1). 
The phosphorylation of the initiation factor 4E-BP1 
on Ser65 was also enhanced, increasing the availability 
of functional eukaryotic initiation factor 4E (eIF4E). 
An increase was also observed in the phosphorylation 
of Rictor on Thr1135, a subunit of mTORC2 complex, 
which is in line with evidence showing that the activation 
of mTORC2 by growth factor signaling is linked to the 
specific phosphorylation of its Rictor component on 
Thr1135 [15].
Figure 1: Identification of modified protein expression or phosphorylation of the mTOR pathway in ACSL4-
overexpressing cells using RPPA. Proteins were extracted from MCF-7 Tet-Off empty vector, MCF-7 Tet-Off/ACSL4 cells and 
doxycycline-treated MCF-7 Tet-Off/ACSL4 (Doxy, 1 ug/ml, 48 h) cells and subjected to RPPA. Protein expression levels are presented as 
fold changes in MCF-7 Tet-Off/ACSL4 cells and doxycycline-treated MCF-7 Tet-Off/ACSL4, both compared to MCF-7 Tet-Off empty 
vector cells. Data refer to upstream regulators A. and components and substrates B. of the mTOR pathway.
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Another interesting phosphoprotein that is 
modulated by ACSL4 expression is the protein encoded by 
gene PRKAA1 (AMPK or protein kinase, AMP-activated, 
alpha 1 catalytic subunit). When phosphorylated, this 
protein negatively regulates the mTORC1 complex by 
phosphorylating its Raptor (regulatory-associated protein 
of mTOR) component and phosphorylating and activating 
the tuberous sclerosis complex 2 (TSC2) [16].
TSC2 (also known as tuberin) forms a heterodimer 
with TSC1 (also known as hamartin), which negatively 
regulates mTORC1 signaling [12, 17]. ACSL4 expression 
reduces the phosphorylation levels of TSC2 on Thr172, 
decreasing its activity and inactivating the TCS1/2 
complex. The phosphorylation and the inhibition of 
TSC2 by AKT is the earliest link between mTORC1 and 
a pathway dysregulated in cancer [12]. This observation 
reinforce the participation of mTORC1 in ACSL4 
signature. In addition, we observed an increase in the 
phosphorylation of AKT on Ser308 and 473, and AKTS1 
(AKT1 Substrate 1, Proline-Rich/PRAS40) on Thr246. 
The mTORC2 complex phosphorylates AKT on Ser473, 
and these results add up to the well-known fact that the 
activation of AKT places mTOR on both sides of AKT 
signaling [18].
Table 1: Functional annotation analysis of RPPA data from ACSL4-overexpressing MCF-7 cells using the bioinformatic 
program DAVID
Term Genes % p-value
Insulin signaling pathway 15 30 5.7E-13
mTOR signaling pathway 10 20 1.3E-10
ErbB signaling pathway 11 22 7.1E-10
Pathways in cancer 17 24 9.5E-10
Prostate cancer 10 20 1.8E-8
Adipocytokine signaling 
pathway 9 18 3.3E-8
Chronic myeloid 
leukemia 9 18 8.1E-8
Acute myeloid leukemia 8 16 2.4E-7
Pancreatic cancer 8 16 1.1E-6
Small cell lung cancer 8 16 3.1E-6
Colorectal cancer 8 16 3.1E-6
Neurotrophin signaling 
pathway 9 18 4.0E-6
Glioma 7 14 7.8E-6
p53 signaling pathway 7 14 1.2E-5
Apoptosis 7 14 5.1E-5
Focal adhesion 9 18 1.3E-4
Melanoma 6 12 2.1E-4
Cell cycle 7 14 3.8E-4
Chemokine signaling 
pathway 8 16 5.4E-4
Endometrial cancer 5 10 6.8E-4
Non-small cell lung 
cancer 5 10 7.8E-4
Enriched terms of KEGG_PATHWAY database were used for the analysis. The p-value is calculated as modified Fisher Exact 
p-value for gene enrichment analysis. It ranges from 0 to 1, with Fisher Exact p-value = 0 representing perfect enrichment. 
Usually p-values equal to or lower than 0.05 are considered strongly enriched in the annotation categories. Percentages refer 
to number of genes involved over total of genes in the term.
Oncotarget42636www.impactjournals.com/oncotarget
GSK3α and GSK3β are critical negative regulators 
of diverse signaling pathways, including mTOR [19]. 
These are two additional phosphoproteins whose levels 
exhibit an important increase in response to ACSL4 
expression, and whose phosphorylation on Ser21 and 
Ser9, respectively, inhibits GSK3 activity and therefore 
contributes to mTOR activation [20, 21]. ACSL4 
expression also stimulates the protein levels of growth 
factors and their receptors, such as the insulin-like growth 
factor binding protein (IGFBP2), also an upstream 
regulator of mTOR. ACSL4 expression decreases the 
protein levels of insulin receptor substrate 1 (IRS1), 
whose recruitment in insulin pathway can activate 
mTORC1 through AKT activation. In turn, the activation 
of p70S6K by mTORC1 promotes the phosphorylation of 
IRS1 and reduces its stability, an auto-regulatory pathway 
or negative feedback loop that has been shown to have 
profound implications for both metabolic diseases and 
tumorigenesis [22, 23].
It is known that both in normal and transformed 
cells the focal adhesion kinase (FAK) increases cell 
motility. This effect is activated by FAK phosphorylation 
on Tyr397 [24], an event in turn enhanced by ACSL4 
expression. FAK protein expression is elevated in many 
highly malignant human cancer types, and studies have 
shown that FAK signaling can promote changes in cell 
shape and the formation of podosomes or invadopodia, 
which in turn leads to an invasive cell phenotype [24]. 
GSK3β has also been implicated in the negative regulation 
of FAK activity [24].
The specificity of ACSL4 was established by the 
specific inhibition of its expression in doxycycline-
treated MCF-7 Tet-Off/ACSL4 cells. In this case, RPPA 
data showed a pattern similar to that of MCF-7 Tet-Off 
empty vector, further supporting the role of ACSL4 in 
the effects observed. All these findings suggest that the 
mTOR pathway is part of the signal transduction involved 
in ACSL4 effects. In addition, RPPA analyses confirmed 
previous findings showing that ACSL4 negatively 
regulates ERα protein expression (Figure 1). This effect 
was reversed by doxycycline treatment, which again shows 
the specificity of the effects triggered by ACSL4 and the 
inverse relationship between ACSL4 and ERα. A KEGG 
pathway map scheme obtained from DAVID analysis [11] 
using the RPPA data shows ACSL4- regulated proteins 
involved in the mTOR pathway (Figure 2).
Identification of ACSL4-responsive genes 
in MCF-7 Tet-Off/ACSL4 cells through 
transcriptome analysis
We next focused on the identification of ACSL4-
responsive genes in MCF-7 Tet-Off/ACSL4 cells 
compared with MCF-7 Tet-Off empty vector cells and only 
considered loci rendering a log2 (fold change) > 2 between 
MCF-7 Tet-Off/ACSL4 and MCF-7 Tet-Off empty vector. 
Out of 32247 successfully sequenced loci, 3944 were 
significantly and differentially expressed in MCF-7 Tet-
Off/ACSL4 samples. Among them, 2501 were upregulated 
and 1443 were downregulated. Using Ingenuity Pathway 
Figure 2: Description of ACSL4 effects on mTOR signaling pathway components. The mTOR pathway scheme was obtained 
from KEGG_PATHWAY database. Analysis was performed by means of the DAVID bioinformatic tool on the basis of RPPA data. Red stars 
highlight ACSL4-regulated proteins in RPPA.
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Analysis (IPA) [25], enriched functional categories of 
gene networks were ranked relating to the transcripts 
regulated in ACSL4-responsive gene sets acquired from 
the RNA-Seq data. When ACSL4 was expressed, analyses 
showed cancer to be the disease with the lowest p-value 
among diseases and disorders. The top three biofunctions 
which were IPA-predicted to be increased in RNA-Seq 
data were cell movement, migration and proliferation. 
Enriched canonical pathways were also analyzed through 
IPA, which interestingly revealed p70S6K, mTOR and the 
signaling of molecular mechanisms of cancer to be among 
the top canonical pathways triggered by ACSL4 with the 
lowest p-values (Table 2).
In other words, the ingenuity canonical pathways 
obtained with the ACSL4 transcriptome signature correlate 
with the ACSL4-functional proteomic signature, where the 
AKT-mTOR-p70S6K signaling pathway seems to be one 
of the most important ACSL4 signatures.
Supplementary Tables S1 and S2 also show ACSL4-
regulated genes related to the mTOR pathway and eIF4 
and p70S6K signaling, respectively. An important number 
of well-known genes were observed which are involved in 
mTOR signaling and regulate cell growth by controlling 
mRNA translation, ribosome biogenesis, autophagy and 
metabolism. In addition, results from RNA-Seq showed 
that ACSL4 overexpression causes a strong reduction 
in the expression of WIF1. The protein encoded by this 
gene inhibits WNT (Wingless-Type MMTV Integration 
Site Family) proteins, which are extracellular signaling 
molecules playing a role in embryonic development. In 
particular, ACSL4 increased the expression of WNT6 and 
WNT10A.
In summary, these results further suggest that 
the mTOR signaling pathway, as well as upstream and 
downstream regulators of mTOR, are part of the targets 
of ACSL4 effects.
Table 2: Enriched canonical pathways in ACSL4-overexpressing MCF-7 cells
Ingenuity Canonical Pathways −log(p-value)
EIF2 Signaling 21.2
Protein Ubiquitination Pathway 14.6
Regulation of eIF4 and p70S6K Signaling 8.88
Molecular Mechanisms of Cancer 8.26
mTOR Signaling 8.18
Mitochondrial Dysfunction 7.47
NRF2-mediated Oxidative Stress Response 6.88
Cell Cycle: G1/S Checkpoint Regulation 6.81
ATM Signaling 6.81






Antiproliferative Role of TOB in T Cell Signaling 5.12
Pancreatic Adenocarcinoma Signaling 4.94
D-myo-inositol (1,3,4)-trisphosphate Biosynthesis 4.76
ERK5 Signaling 4.66
Type II Diabetes Mellitus Signaling 4.66
Hereditary Breast Cancer Signaling 4.55
TGF-β Signaling 4.55
IPA analysis of RNA-Seq data towards canonical pathways. Pathways are shown which were designated significantly 
enriched by the software, with a p-value < 0.05 by Fisher’s Exact test.
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Lipoxygenase metabolites mediation of ACSL4 
effects on the mTOR pathway
We have previously reported the involvement of 
AA lipoxygenase-5 (LOX-5) metabolites in the action 
of ACSL4 on cell proliferation and tumor growth 
[4, 6]. Considering the results showed above indicating 
that ACSL4 might be a novel regulator of mTOR, we 
next validated these results evaluating whether these 
metabolites are involved in ACSL4 effects on mTOR 
signaling. For this purpose, we used zileuton to inhibit 
LOX-5 as previously described [4, 6]. MCF-7 Tet-Off/
ACSL4 cells were treated as shown in Materials and 
Methods and cell lysates were analyzed by Western 
blot using p70S6K (Thr389), S6 (Ser235/236), Rictor 
(Thr1135), GSK3αβ (Ser21/9) and GSK3 antibodies as 
reference for the mTOR signal. LOX-5 inhibition reduced 
the phosphorylation of p70S6K and Rictor (Figure 3) and 
inhibited cell proliferation (data not shown) as previously 
described [4, 6], demonstrating that lipoxygenase 
metabolites are in part the mediators of ACSL4 effects on 
the regulation of the mTOR pathway.
Validation of ACSL4 effects on the mTOR 
pathway
Considering the results shown above indicating that 
ACSL4 might be a novel regulator of mTOR, we further 
analyzed the mTOR pathway by Western blot using the 
same cell model used in the RPPA analysis and two 
additional breast cancer cell models. We measured the 
basal expression level of some of the mTOR signaling 
and related molecules, along with the effect of the up and 
downregulation of ACSL4 expression.
As shown in Figure 4, ACSL4 protein levels were 
significantly upregulated in the MCF-7 Tet-Off/ACSL4 
cells, as compared to MCF-7 Tet-Off empty vector 
cells, and returned to basal levels in the lyses obtained 
from doxycycline-treated MCF-7 Tet-Off/ACSL4 cells, 
confirming that this model is useful to analyze the role 
of ACSL4. A significant increase in the phosphorylation 
of p70S6K on Thr389 and its substrate, ribosomal 
protein S6, on Ser235/236 showed that mTORC1 is 
activated by ACSL4 expression. An increase was also 
observed in the phosphorylation of Rictor on Thr1135, 
substrate of p70S6K and component of mTORC2 
complex. In addition, the enhancement detected in AKT 
phosphorylation on Ser473 indicates that its kinase, 
mTORC2, is also activated by ACSL4 expression. 
GSK3α and GSK3β phosphorylation levels on Ser21/9, 
and not total GSK3 levels, were increased in response to 
ACSL4 expression; GSK3 activity was thus inhibited and 
contributed to mTOR activation.
These results confirmed those obtained by RPPA. 
As expected, the doxycycline treatment of MCF-7 Tet-
Off/ACSL4 cells resulted in the inhibition of the effect 
observed with the overexpression of ACSL4 (Figure 4).
Effects of ACSL4 expression on the mTOR 
pathway in T47D cells
In order to further evaluate the effect of ACSL4 
expression on the mTOR pathway observed with the 
MCF-7 Tet-Off/ACSL4 cells, we next produced an 
ACSL4-overexpressing system using a different non-
aggressive breast cancer cell line, i.e. T47D cells. (T47D 
ACSL4) (Figure 5). The basal expression levels of some of 
the mTOR signaling and related molecules were measured 
Figure 3: Role of LOX-5 metabolites in ACSL4 effects on the mTOR pathway. MCF-7 Tet-Off/ACSL4 cells were incubated 
in the presence or absence of zileuton (LOX-5 inhibitor, 500 μM) for 24 h. Whole cell extracts were obtained as described in Materials and 
Methods. Western blot was performed using the indicated antibodies. Representative blots A. and integrated optical density of protein levels 
B. quantified and normalized with the corresponding β-tubulin signal. Data represent the means of percentages of inhibition ± SD of three 
independent experiments. ***p < 0.001 and **p < 0.01 vs. control cells.
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by Western blot analysis, together with the effect of 
ACSL4 upregulation. Consistent with the results described 
above, the phosphorylation pattern of mTOR related to 
phosphoprotein levels observed in T47D-ACSL4 cells was 
the same as that observed in MCF-7 Tet-Off/ACSL4 cells.
Effects of ACSL4 knockdown on the mTOR 
pathway in MDA-MB-231 cells
Given that overexpression experiments could force 
ACSL4 action, and to further validate the results described 
above through a control experiment, we next disrupted 
the expression of endogenous ACSL4 using small hairpin 
RNA (shRNA) in the highly aggressive MD-MB-231 
breast cancer cells, which constitutively overexpress 
ACSL4. Western blot analyses showed that the shRNA 
targeting ACSL4 markedly decreased the expression of 
ACSL4 protein approximately by 40% (Figure 6). ACSL4 
knockdown markedly decreased the protein levels of 
p70S6K (Thr389) and its substrates, S6 (Ser235/236) and 
Rictor (Thr1135), indicating that mTORC1 activity was 
reduced. GSK3α and β phosphorylation levels (Ser21/9), 
and not total GSK3 levels, were decreased in response 
to ACSL4 knockdown, indicating that GSK3 was active 
and thus contributed to mTOR inhibition. Concomitantly 
with the reduction observed in the mTOR signal, 
there was a significant reduction in cell proliferation, 
invasion and migration (data not shown), as previously 
described [6]. Remarkably, ACSL4 knockdown increased 
ERα expression, confirming the regulation of ER protein 
expression by ACSL4 (Figure 6).
Inhibition of cell proliferation through the 
combination of sub-effective doses of ACSL4  
and mTOR inhibitors
Rapamycin, a macrolide fungicide, has generated 
significant interest as a potential anticancer drug. 
Rapamycin inhibits mTOR by binding to one of the 
members of the immunophilin family of FK 506-binding 
proteins (FKBP12) [26, 27].
In this context, and in order to validate a potential 
clinical significance of the novel effect of ACSL4 on 
mTOR, we used a combined pharmacological approach 
involving rapamycin in combination with rosiglitazone, 
an inhibitor of ACSL4 activity [28, 29], to elucidate the 
signaling mechanism underlying ACSL4 impact on cell 
proliferation. To examine the sensitivity of MCF-7 Tet-Off/
ACSL4 cells to rapamycin, cells were treated at different 
concentrations (1–1000 nM) for 4 days and cell proliferation 
was measured by BrdU (5-bromo-2′-deoxyuridine) 
incorporation and MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazoliumbromide) assays as described in 
Materials and Methods. The minimal dose of rapamycin 
that produced a significant inhibition was 10 nM, while, as 
previously described, the minimal dose of rosiglitazone to 
Figure 4: Validation of ACSL4 effects on the mTOR pathway in MCF-7 cells. Whole cell extracts were obtained as described 
for RPPA from MCF-7 Tet-Off empty vector, MCF-7 Tet-Off/ACSL4 and doxycycline-treated MCF-7 Tet-Off/ACSL4 cells (Doxy, 1 ug/
ml, 48 h). Western blot was performed using the indicated antibodies. Representative blots A. and integrated optical density of protein 
levels B. quantified and normalized with the corresponding β-tubulin signal. As shown in Figure 1, data represent the means of fold changes 
± SD of three independent experiments. a, b, c, d and e: ***p < 0.001; f and g: *p < 0.05 vs. MCF-7 Tet-Off empty vector cells.
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produce a significant inhibition was 75 μM. Therefore, we 
used these submaximal doses of the inhibitors in order to 
observe the efficacy of this combination of drugs. Figure 
7 describes the results obtained using BrdU incorporation, 
since both MTT and BrdU assays showed the same results. 
Treatment with 10 nM rapamycin or 75 μM rosiglitazone 
produced a significant inhibition on MCF-7 Tet-Off/
ACSL4 cell proliferation. Interestingly, the combination 
of these drugs enhanced the inhibition of cell proliferation, 
suggesting the potential for additive, synergistic inhibitory 
effects. Moreover, the same synergistic effect was observed 
for inhibitor combination on p-S6 protein levels, a 
representative component of mTOR signaling (Figure 7, 
inset).
The same approach used to treat MCF-7 Tet-Off 
empty vector cells revealed low but significant inhibition 
produced by rapamycin treatment but no combined 
inhibitory effect of these drugs. A possible explanation for 
this finding may involve the low expression of ACSL4 in 
these cells and, therefore, little contribution of ACSL4 to 
mTOR activity.
When the effect of these drugs was analyzed in 
the highly aggressive MDA-MB-231 breast cancer cells, 
which constitutively overexpress ACSL4, no effects were 
observed for rapamycin at any concentrations (data not 
shown). The lack of response to rapamycin treatment of 
MDA-MB-231 cells has been previously described by 
other authors [30]. As an explanation for this finding, 
mTOR may potentially activate cell growth in very 
aggressive cells by mechanisms other than its well-
known nutrient-sensitive multiprotein complex. In turn, 
sensitivity to rosiglitazone could be explained by the 
Figure 5: ACSL4 effects on the mTOR pathway in T47D cells. T47D cells were transfected with the plasmid containing ACSL4 
cDNA (T47D-ACSL4) or empty plasmid (T47D empty vector). Forty-eight hours post transfection, cells were selected with G418 (500 μg/
ml) antibiotic. One month post selection, whole cell extracts were obtained and analyzed by Western blot using the indicated antibodies. 
Representative blots A. and integrated optical density of protein levels B. quantified and normalized with the corresponding β-tubulin 
signal. Data represent the means of fold changes (T47D-ACSL4 vs. T47D empty vector) ± SD of three independent experiments. Dotted 
line indicates control values. a, b, c, d, e and f: ***p < 0.001 vs. T47D empty vector cells.
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fact that MDA-MB-231 breast cancer cells express very 
high levels of ACSL4 and, as shown in the results above, 
ACSL4 affects the up and downregulators of mTOR and 
regulates mTORC1 and mTORC2 activities.
Inhibition of cell proliferation through 
the combination of sub-effective doses 
of rosiglitazone and 4-hidroxitamoxifen 
(4-OHTAM)
We have shown that knocking down ACSL4 
expression in the aggressive triple negative breast 
cancer cell line MDA-MB-231 induces ERα expression 
(Figure 6). As expected, and in agreement with previous 
results [4], ACSL4 overexpression decreased the level of 
ERα (see Figure 1). In our interpretation of these data, the 
inhibition of ACSL4 might force the tumor to restore the 
estrogen signaling pathway for continuous growth and 
hormonal sensitivity, which is why the blockade of both 
the ACSL4 and estrogen pathways together might leave 
the tumor with extremely few options.
By means of the MCF-7 Tet-Off/ACSL4 model 
system, which involves a reduction in ERα levels, we used 
a pharmacological approach to inhibit cell proliferation 
through a combination of sub-maximal doses of tamoxifen 
(4-OHTAM) and rosiglitazone. As shown in Figure 
8A, treatment with the inhibitors alone did not produce 
a significant inhibition in cell proliferation. However, 
the combination of the two inhibitors was much more 
efficient in inhibiting cell proliferation than 4-OHTAM or 
rosiglitazone individually, showing a remarkable synergistic 
effect. These results open up the possibility for inhibitor 
Figure 6: ACSL4 effects on the mTOR pathway in MDA-MB-231 cells. MDA-MB-231 cells were transfected with the pSUPER.
retro plasmid containing a shRNA targeted to ACSL4 (shRNA-ACSL4) or an empty plasmid (mock). Forty-eight hours post transfection, 
cells were selected with puromycin (1 μg/ml) antibiotic. One month post selection, whole cell extracts were obtained and analyzed by 
Western blot as previously described using the indicated antibodies. Representative blots A. and integrated optical density of protein 
levels B. quantified and normalized with the corresponding β-tubulin signal. Data represent the means of fold changes (shRNA-ACSL4 
vs. mock) ± SD of three independent experiments. Dotted line indicates control values. a, b, c, d, f and g: ***p < 0.001; e: **p < 0.01 vs. 
mock transfected cells.
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combinations which might prevent the loss of hormonal 
response in tumors that begin to overexpress ACSL4 
and begin to reduce the levels of ER. Levels of ERα, 
p-S6, p-GSK3αβ, p-AKT (Ser473) and p-p70S6K were 
monitored to confirm that rosiglitazone treatment indeed 
increased ERα expression and decreased the mTOR signal 
as expected (Figure 8B). These results are in agreement 
with previous results showing that mTOR inhibition by 
rapamycin reverses acquired endocrine therapy resistance 
of breast cancer cell and cell proliferation [31].
Since, as described above, the triple negative MDA-
MB-231 breast cancer cells are sensitive to rosiglitazone, we 
also studied whether the inhibition of ACSL4 activity could 
reverse ER therapy resistance in cells that do not express ER. 
Figure 9 shows the effect of a combination of rosiglitazone 
and 4-OHTAM on cell proliferation. The combination of 
the two inhibitors was much more efficient in inhibiting cell 
proliferation than 4-OHTAM or rosiglitazone individually. 
Figure 9 inset shows again that rosiglitazone treatment indeed 
increased ERα expression, as shown in Figure 8B. Again, 
these results suggest promising inhibitor combinations which 
might prevent the loss of hormonal response in triple negative 
tumors overexpressing ACSL4.
In vivo therapy of solid tumors in mice
On the basis of our previous in vitro results and the 
demonstration that modulating ACSL4 inhibition results 
in the upregulation of ER with a consequent change in 
cell phenotype and the sensitivity of tamoxifen, the logical 
next step was to analyze the effect of ACSL4 inhibitor and 
tamoxifen on tumor growth in vivo.
The MDA-MB-231 cell line is known to form 
tumors with a triple negative signature that do not respond 
to hormone treatment; therefore, the MDA-MB-231 
xenograft model was a very good challenge to demonstrate 
that ACSL4 inhibitor and ER inhibitor are working in a 
concerted manner and demonstrate a synergistic effect of 
the inhibitors as a potential therapeutic protocol.
For MDA-MB-231 tumor xenografts, four days after 
cell injection the tumor-bearing mice were randomized 
into the following four groups (five animals per group) and 
received intraperitoneal injections and oral administration 
of the respective drugs for 25 consecutive days:
Group 1 (MDA-MB-231 cell xenografts treated with 
vehicle), Group 2 (MDA-MB-231 cell xenografts treated 
with tamoxifen), Group 3 (MDA-MB- 231 cell xenografts 
treated with rosiglitazone), Group 4 (MDA-MB-231 cell 
xenografts treated with a combination of the two drugs at 
the same doses used for the individual injections).
Although the MDA-MB-231 xenograft growth rate 
varies among studies reported in the literature, our tumor 
xenografts were in the range of those previously reported 
[24]. The average animal body weight was 23.5 g at the 
beginning of the treatment and no significant differences in 
body weight were observed between the different treatment 
groups at the end of the experiment. The amount of food 
intake in the control compared to the treated groups was 
Figure 7: Cell proliferation inhibition by combining sub-effective doses of ACSL4 and mTOR pathway inhibitors. MCF-7 
Tet-Off empty vector and MCF-7 Tet-Off/ACSL4 cells were plated at a density of 4000 cells/well in 96-well plates with 10% FBS-
supplemented D-MEM medium and allowed to adhere overnight at 37°C in a humidified 5% CO2 atmosphere. The medium was then 
changed to serum-free medium. After 24 h, the cells were switched to 10% FBS-supplemented D-MEM medium with rapamycin (10 nM) 
and/or rosiglitazone (75 μM) for 96 h. Subsequently, cell proliferation was measured by BrdU incorporation assays as described before [6]. 
Data are presented as inhibition of cell proliferation compared to control cells. White bars indicate a single inhibitor treatment while grey 
bars indicate combined inhibitor treatment. Data are presented as means ± SD. a: ***p < 0.001 vs. single inhibitors. Inset: MCF-7 Tet-Off/
ACSL4 cells were incubated in the presence or absence of rosiglitazone (75 μM) alone or in combination with rapamycin (10 nM) for 48 h. 
p-S6 protein levels were evaluated by Western blot and a representative blot is shown.
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Figure 8: Cell proliferation inhibition by combining sub-effective doses of ACSL4 and ER pathway inhibitors. MCF-7 Tet-Off/
ACSL4 cells were plated as described in Figure 7 and then incubated with rosiglitazone (10 or 25 μM) and/or 4-hidroxitamoxifen (4-OHTAM 
2.5 or 5 μM) for 96 h. Subsequently, cell proliferation was measured by BrdU incorporation assays A.. Data are presented as inhibition of cell 
proliferation compared to control cells. White bars indicate a single inhibitor treatment while grey bars indicate combined inhibitor treatment. Data 
are presented as means ± SD. a, b, c, and d: ***p < 0.001 vs. corresponding single inhibitors; e: ***p < 0.001 vs. 4-OHTAM 2.5 μM + rosiglitazone 
10 μM. MCF-7 Tet-Off/ACSL4 cells were incubated in the presence or absence of rosiglitazone (75 μM) alone or in combination with GW9662 
(10 μM) for 24 h. ERα and mTOR-related protein levels were evaluated by Western blot and a representative blot is shown B..
Figure 9: Cell proliferation inhibition by combining sub-effective doses of ACSL4 and ER pathway inhibitors in 
MDA MB-231 cells. MDA-MB-231 cells were plated as described for MCF-7 Tet-Off/ACSL4 cells in Figure 7 and then incubated with 
rosiglitazone (100 μM) and/or 4-hidroxitamoxifen (4-OHTAM 7.5 or 10 μM) for 96 h. Subsequently, cell proliferation was measured by 
BrdU incorporation assays. Data are presented as inhibition of cell proliferation compared to control cells. White bars indicate a single 
inhibitor treatment while grey bars indicate combined inhibitor treatment. Data are presented as means ± SD. a and b: ***p < 0.001 vs. 
corresponding single inhibitors. Inset: MDA-MB-231 cells were incubated in the presence or absence of rosiglitazone (100 μM) for 48 h. 
ERα protein levels were evaluated by Western blot and a representative blot is shown.
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not significantly different throughout the experiment. 
However, there was a significant inhibition in average 
tumor volume and growth rate in animals subjected to 
combination therapy compared to those that received single 
drug-based treatments or drug vehicle after injection of 
MDA-MB-231 cells (Figure 10A and 10B, respectively). 
The tumors from mice treated with drug combination were 
clearly smaller than those from either the control group or 
single drug treatment groups.
DISCUSSION
This study was undertaken to elucidate the signal 
transduction involved in the effects of ACSL4 on cell 
growth. Even though it was previously demonstrated that 
this enzyme plays a causal role in the control of breast 
cancer aggressiveness, the mechanism underlying this 
process has yet to be fully elucidated.
In the present work we demonstrate that ACSL4 
can be considered a novel activator of the mTOR 
pathway, for both mTORC1 and mTORC2 components, 
and that ACSL4 expression can trigger several different 
mechanisms to regulate mTOR.
The specificity of ACSL4 action on mTOR signaling 
was assessed by the specific inhibition of ACSL4 
expression by doxycycline in the MCF-7 Tet-Off/ACSL4 
model, by the expression of ACSL4 in the non-aggressive 
T47D breast cancer cell line and by the downregulation 
of ACSL4 expression in the very aggressive MDA-
MB-231 breast cancer cells that constitutively expresses 
ACSL4. mTOR comprises a rapamycin- and nutrient-
sensitive multiprotein complex (mTORC1) and a growth 
factor-sensitive nutrient-insensitive complex (mTORC2). 
A direct regulation of mTOR activity by ACSL4 is 
demonstrated by the fact that ACSL4 expression increases 
the phosphorylation of mTOR on Ser2448.
A major leap forward in understanding mTORC1 
regulation was the discovery that TSC1/2 bipartite 
protein complex negatively controls its activity [12, 32]. 
Mutations in either the tsc1 or the tsc2 genes cause the 
hamartomatous syndrome tuberous sclerosis complex 
(TSC) [32]. The discovery of the connection between 
TSC and mTORC1 pathway provided the first molecular 
link between mTOR and cancer. ACSL4 contributes 
to the regulation of the TSC1/2 complex is through 
the decrease in the phosphorylation levels of AMPK 
phosphoprotein on Thr172 decreasing its activity and 
inactivating the TCS2 complex. As mentioned before, 
this phosphoprotein negatively regulates the mTORC1 
complex by phosphorylating its Raptor component and 
phosphorylating and activating TCS2 [12]. These results 
strongly suggest that ACSL4 expression modulates at least 
Figure 10: Effect of ACSL4 and ER pathway inhibitors in the MDA-MB-231 human breast xenograft model. Mice 
bearing MDA-MB-231 tumor xenografts were treated with either vehicle (control), rosiglitazone or tamoxifen alone, or with a combination 
of the two inhibitors at doses described in Materials and Methods for 26 consecutive days. Comparison of average tumor volume  
A. and tumor growth rate between days 20–30 B. was determined. Data are presented as means ± SD, n = 5. Asterisks indicate significant 
differences between tumor volumes by two-way ANOVA (A) and between tumor growth rates by one-way ANOVA (B). ns vs. single 
inhibitors; *p < 0.05, **p < 0.01, ***p < 0.001 vs. corresponding single inhibitors.
Oncotarget42645www.impactjournals.com/oncotarget
two separate signaling pathways which are conjectured to 
control mTOR activity.
An additional mechanism through which 
ACSL4 regulates mTOR activity is the increase in the 
phosphorylation of AKT1S1. AKT participates in mTORC1 
activation in an independent fashion by phosphorylating 
AKT1S1, causing its dissociation from Raptor and 
suppressing mTORC1 inhibition.
Diverse signals regulate TSC1/2, which suggests 
that, like mTORC1, TSC1/2 is a signal integration center. 
Positive growth signal from RAS-MAPK pathway inhibits 
TSC2, although the phosphorylation and inhibition of 
TSC2 by AKT are the clearest links between mTORC1 
and pathway deregulation in cancer [12, 18].
In contrast to growth-factor-driven activation of 
mTORC1, hypoxia, AMPK activation resulting from 
depletion of cellular energy, Wnt-GSK3 signaling and 
glucocorticoids all inhibit mTORC1 by promoting TSC1/2 
activation [19, 33, 34]. The phosphorylation of GSK3 is a 
potent inhibitor of its activity and our results clearly show 
that ACSL4 expression increase the phosphorylation of 
GSK3αβ. As GSK3 has been shown to inhibit the Wnt 
signaling pathway, the inhibition of GSK3 activity by 
phosphorylation suggests that Wnt signaling is part of the 
mechanism of action of ACSL4 expression.
The aberrant regulation of the Wnt signaling pathway 
is a prevalent theme in cancer. From early observations 
that WNT overexpression could lead to malignant 
transformation of mouse mammary tissue to the most recent 
genetic discoveries gleaned from tumor genome sequencing, 
the Wnt pathway continues to evolve as a central 
mechanism in cancer biology [35, 36]. Results from RNA-
Seq also show that ACSL4 overexpression caused a strong 
reduction in the expression of WIF1 and an increase in the 
expression of WNT6 and WNT10A. In agreement with 
our results, a requirement for ACSL4 and the involvement 
of GSK3 has recently been demonstrated in dorsoventral 
pattering of zebrafish embryo [37] and embryogenesis 
and neurogenesis in Drosophila [38, 39]. These results 
show that ACSL4 works through the inhibition of AKT-
dependent GSK3 activity by increasing its phosphorylation. 
And, given the interplay between morphogenic signals in 
developing embryos, the interaction of these pathways has 
been suggested to be involved in cancer.
An important concern in the field is whether cancer 
can survive by acquiring adaptations that allow mTORC1 
to continue signaling in a poor nutrient and oxygen 
environment. Because deprivation of energy, oxygen and 
nutrients is common in the microenvironment of tumors, 
cancer cells which are insensitive to these types of stress 
may have a selective growth advantage. Consistent with 
this idea, tsc2-deficient cells undergo apoptosis in glucose-
free medium, a response suppressed by rapamycin [12].
mTOR also drives protein synthesis by regulating 
ribosome biogenesis. In yeast, mTORC1 activity 
promotes the synthesis of ribosomal proteins, which 
in higher organisms may additionally or alternatively 
involve regulating ribosome assembly [12]. As shown 
in Supplementary Tables S1 and S2 ACSL4 expression 
regulates genes associated with ribosome biogenesis 
and ribosome assembly. These results suggest that the 
expression of ACSL4 regulates mTOR activity and cell 
growth from diverse signals and may also control mTOR 
activity by regulating its upstream signaling and effectors. 
In this context, p70S6K is one of the major downstream 
components of the mTOR signaling pathway. Phospho-
p70S6K (Thr389) was one of the phosphoproteins present 
in high levels in the MCF-7 Tet-Off/ACSL4 and T47D 
ACSL4 cells and in low levels in MDA MB 231 shACSL4 
cells, which indicates that p70S6K is regulated by ACSL4. 
Phospho-S6 protein (Ser235/236) was also present at 
similar levels in these cell lines, once again showing a 
direct correlation between the regulation of mTOR activity 
by ACSL4 and the marked increase in mTORC1 effectors.
In many cell types, activation of mTORC1 signaling 
strongly represses PI3K-AKT signaling upstream in the 
PI3K. For example, loss of TSC1/2 function results 
in decreased AKT phosphorylation. One mechanism 
by which this occurs appears to be through p70S6K-
dependent downregulation of IRS1. When mTORC1 
is active, phospho-p70S6K directly phosphorylates 
and inhibits IRS1. This may be the case in the action 
of ACSL4, as there is a regulation of IRS1. In addition, 
ACSL4 increases the phosphorylation of TSC1/2 
complex and thus inactivates it. TSC1/2 could therefore 
be inactivated by several mechanisms (including AKT, 
extracellular-signal-regulated kinase 1/2 (ERK1/2) and 
p70S6K — and thus, activate mTORC1.
Studies defining mTORC2 cellular functions and 
signaling have lagged behind, although the finding that 
mTORC2 directly phosphorylates AKT adds a new 
twist in the consideration of the role of mTOR in cancer. 
mTORC2 also includes the mLST8 protein but, in contrast 
with mTORC1, contains Rictor rather than Raptor. ACSL4 
expression increases the phosphorylation of Rictor and also 
of AKT in Ser473. Phosphorylation of Ser473 in C-terminal 
hydrophobic motif is necessary for full activation of AKT. 
Several kinases have been proposed to fulfill the role of 
the AKT (Ser473) kinase/PDK2 kinase. mTOR was added 
to the list as a result of loss-of-function RNAi experiments 
coupled with in vitro biochemistry in Drosophila and in 
human cancer cells [18]. This study and ensuing work in 
human adipocytes and Dictostylium show that depletion of 
Rictor or mTOR, but not Raptor, dramatically reduce AKT 
(Ser473) phosphorylation [18, 40]. In Dictostylium PIA, the 
ortholog of Rictor physically interacts in a complex and, 
when mutated, induces similar phenotype or impaired AKT 
activation. Subsequent biochemical studies in mammalian 
and Drosophila culture cells confirm these observations 
[41]. These findings provide strong genetic evidence in 
mammals to substantiate the claim that mTORC2 directly 
regulates AKT (Ser473). Expression of ACSL4 increases 
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AKT (Ser473) levels and the phosphorylation of Rictor. 
These results strongly support the concept that ACSL4 
acts on the two components of mTOR, the rapamycin 
and nutrient-sensitive multiprotein complex and also the 
nutrient-insensitive mTOR-containing complex, and may 
help explain the strong capacity of the sole transfection of 
ACSL4 to change the phenotype of breast cancer cells as 
previously described [4]. Taken together, these findings 
show that ACSL4 is a new regulator of mTOR activity 
and up and downstream molecules of mTOR. Therefore, 
together with phospho-p70S6K, phospho-S6 and phospho-
4E-BP1, ACSL4 appears to be a useful predictor of mTOR 
activity and whether breast tumors will respond to the 
inhibition of mTOR.
Experiments were also performed to go deeper into 
the mechanisms by which ACSL4 may regulate mTOR 
activity. ACSL4 is an important enzyme that plays a 
crucial role in the metabolism of AA. Particularly, we 
have demonstrated that ACSL4 promotes cell growth 
and tumor progression in vivo through the release of 
AA and its metabolization to lipoxygenase products 
[4]. Our results show that the lipoxygenase pathway is 
in part involved in the activation of mTOR. AA levels 
have been recently shown to strongly correlate with the 
signaling activity of mTORC1 and mTORC2 in human 
breast tumor tissues. In human breast cancer cells, AA 
effectively activates both mTOR complexes and its 
effect is mediated by lipoxygenase but not cicloxygenase 
metabolites [42]. In addition, it has been reported that AA 
induces FAK activation and migration in MDA-MB-231 
cells [43]. Our RPPA results also show that ACSL4 
increases FAK phosphorylation on Tyr397 and, therefore, 
FAK activity. We have also previously described that 
ACSL4 is a key enzyme in the regulation of lipoxygenase 
and lipoxygenase metabolites of AA in physiological 
conditions such as the regulation of steroidogenesis and in 
pathological conditions such as cancer. However, further 
work is needed to better understand the mechanism 
underlying the regulation of the different signals triggered 
by ACSL4 expression to regulate mTOR activity.
Despite knowing about mTOR for nearly 15 years, 
we are just beginning to appreciate the complexity of the 
mTOR network and to be able to use this pathway as an 
efficient therapeutic target. Although clinical results have 
been obtained with three prototypes of mTOR inhibitors, 
all rapamycin-analogs, clinical updates unfortunately 
indicate that rapamycin shows promising results against 
only few types of cancer. Overall, the therapeutic response 
to rapamycin is highly variable.
As ACSL4 might be a novel regulator of mTOR, the 
combined inhibition of an upstream mechanism such as 
ACSL4 activity and mTOR seems to be a potential target 
to be used in order to avoid compensatory feedback. We 
show here that rapamycin and rosiglitazone, an ACSL4 
inhibitor, can act in combination to inhibit cell growth in 
breast cancer cells. Although ACSL4 was still not related 
to the mTOR pathway, this drug combination has been 
used previously in human non-small lung carcinoma, 
where the inhibitory effect of rosiglitazone on cell 
growth was enhanced by mTOR inhibitor rapamycin 
[44]. Moreover, it has been shown that rosiglitazone 
decreases the phosphorylation of p70S6K in human non-
small lung carcinoma, an effect that was not reversed by 
GW9662, a peroxisome proliferator-activated receptor γ 
(PPARγ) antagonist [44]. We show here (Figure 8B) 
that rosiglitazone decreased the phosphorylation of S6, 
GSK3αβ, AKT (Ser473) and p70S6K, an effect that 
was neither reversed by GW9662. Rosiglitazone has 
been described as a PPARγ agonist. Therefore, it could 
be speculated that the effect of rosiglitazone in these 
experiments could be due to its activation of PPARγ and 
not to ACSL4 inhibition. However, the results described 
above, along with our findings showing that the effects of 
rosiglitazone on breast cancer growth in vitro and in vivo 
are similar to those obtained with the specific inhibition 
of ACSL4 by doxycycline treatment in MCF-7 Tet-Off/
ACSL4 cells [4], strongly suggest that rosiglitazone 
effects are due to the inhibition of ACSL4 activity.
It has been suggested that the increased activation 
of mTOR, possibly through the PI3K/AKT pathways, 
plays a role in the endocrine resistance exhibited by 
some ERα+ breast cancer cells, and that the inhibition of 
mTOR signaling with rapamycin could restore sensitivity 
to 4-OHTAM, an inhibitor of the estrogen pathway, in 
laboratory models of resistance [45]. In agreement with 
these results, we also show that rosiglitazone can be used 
in combination with tamoxifen to inhibit cell growth in 
MCF-7 Tet-Off/ACSL4 cells. As an additional significant 
finding, a combination of rosiglitazone and 4-OHTAM 
was also effective in inhibiting cell proliferation and tumor 
growth in cells that do not express ER and overexpress 
ACSL4, such as the very aggressive triple negative breast 
cancer cell line MDA-MB-231.
Therefore, as ACSL4 regulates ERα expression 
and the mTOR pathway, our results provide evidence that 
ACSL4 could be also an interesting target, in combination 
with 4-OHTAM, to restore tumor hormone dependence 
in tumors with poor prognosis and low survival rates. 
Moreover, as the expression of ACSL4 is negatively 
regulated by estrogen and in turn regulates the levels of 
ERα, the presence of ACSL4 could be a prognostic factor 
for hormone resistance in ERα-positive breast cancer 
tissues that begin to express it. A combined therapy of 
ACSL4 and ERα inhibitors could thus be very useful in 
actually preventing the appearance of hormone resistance.
The possibility of using an ASCL4 inhibitor together 
with rapamycin may provide a useful combinatory therapy 
to target new types of cancer, including breast cancer. And, 
accordingly, designing effective combination therapies 
using ACSL4 and mTOR inhibitors together with agents 
targeting key molecular elements involved in breast 
cancer relies heavily on the identification of predictive 
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markers that may provide the basis for patient therapy. 
Collectively, these findings may change the view of the 
pathological role mTOR plays in cancer and open doors 
to new therapeutic strategies.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle medium (DMEM), 
penicillin-streptomycin solution and trypsin-
EDTA were purchased from GIBCO, Invitrogen 
Corporation (Grand Island, NY, USA). Fetal calf 
serum was from PAA laboratories GmbH (Pasching, 
Austria). Doxycycline, 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazoliumbromide) (MTT) and 
4-hydroxytamoxifen (4-OHTAM) were purchased 
from Sigma Chemical Co. (St. Louis, MO, USA). 
Rapamycin was obtained from Cayman Chemical 
Company (Michigan, IL, USA). GW9662 was obtained 
from Tocris Bioscience (Bristol, UK). Monoclonal 
mouse anti-GSK-3α/β and polyclonal rabbit anti-ERα 
antibodies were from Santa Cruz Biotechnology, Inc. 
(Dallas, TX, USA). Polyclonal rabbit phospho-GSK-
3α/β (Ser21/9), phospho-p70 S6 kinase (Thr398) and 
phospho-S6 ribosomal protein (Ser235/236) antibodies 
were from Cell Signaling Technology (Boston, MA, 
USA). Phospho-AKT (Ser473) and phospho-Rictor 
(Thr1135) rabbit monoclonal antibodies were purchased 
from Cell Signaling Technology (Boston, MA, USA). 
Horseradish peroxidase-conjugated goat anti-rabbit 
and goat-anti-mouse secondary antibodies and Immun-
Blot polyvinylidene fluoride membrane was from Bio-
Rad Laboratories (Hercules, CA, USA). Enhanced 
chemiluminescence (ECL) was from GE Healthcare 
(Buckinghamshire, UK). Direct-zol RNA kit was from 
Zymo Research (Irvine, CA, USA). Sterile and plastic 
material for tissue culture was from Orange Scientific 
(Braine-l’Alleud, Belgium). 5-bromo-2′-deoxyuridine 
(BrdU) cell proliferation ELISA kit was from Roche 
Diagnostics, Basel, Switzerland). All other reagents 
were of the highest grade available.
Cell culture
Human breast cancer cell lines MDA-MB-231, 
MCF-7 and T47D were generously provided by Dr. 
Vasilios Papadopoulos (Research Institute of the McGill 
University Health Centre, Montreal, Canada) and obtained 
from the Lombardi Comprehensive Cancer Center 
(Georgetown University Medical Center, Washington 
D.C., USA). The tetracycline-repressible MCF-7 cell lines, 
designated MCF-7 Tet-Off empty vector, and MCF-7 Tet-
Off-induced repression of ACSL4, designated MCF-7 Tet-
Off/ACSL4 were obtained previously in the laboratory [6].
For transfection of MDA-MB-231 and T47D, 
cells were seeded the day before and grown up 
to 80% confluence. Transfection was performed 
in Opti-MEM medium with Lipofectamine 2000 
reagent (Invitrogen) using the pSUPER.retro plasmid 
(OligoEngine, Seattle, WA, USA) containing ACSL4 
shRNA (AAGATTATTCTGTGGATGA) for the MDA-
MB-231 cells and the pcDNA3.1(+) (Invitrogen) 
plasmid containing ACSL4 cDNA for the T47D cells. 
The respective empty vectors were used as controls. 
Transfection efficiency was estimated by counting 
fluorescent cells transfected with the pRc/CMVi [11] 
plasmid containing the enhanced form of green fluorescent 
protein. Forty-eight hours after transfection, cells were 
selected in media containing 500 μg/ml G418 and 1 μg/ml 
Puromycin for 1 month and then collected for biochemical 
and cellular assays. T47D and MDA-MB-231 transfected 
cell lines were designated T47D-ACSL4, T47D empty 
vector, MDA-MB-231 shRNA-ACSL4, and MDA MB 231 
mock, respectively.
Reverse phase protein assay (RPPA)
RPPA was performed in the RPPA Core Facility 
- Functional Proteomics from MD –Anderson Cancer 
Center, University of Texas, USA. Cellular proteins 
were denatured by 1% SDS (with β-mercaptoethanol) 
and diluted in five 2-fold serial dilutions in dilution 
buffer (lysis buffer containing 1% SDS). Serial diluted 
lysates were arrayed on nitrocellulose-coated slides 
(Grace Biolab) by Aushon 2470 Arrayer (Aushon 
BioSystems). Total 5808 array spots were arranged on 
each slide including the spots corresponding to positive 
and negative controls prepared from mixed cell lysates or 
dilution buffer, respectively. Each slide was probed with 
a validated primary antibody plus a biotin-conjugated 
secondary antibody. Only antibodies with a Pearson 
correlation coefficient between RPPA and western blotting 
greater than 0.7 were used in RPPA studies. Antibodies 
with a single or dominant band on western blotting were 
further assessed by direct comparison to RPPA using cell 
lines with differential protein expression or modulated 
with ligands/inhibitors or siRNA for phospho- or 
structural proteins, respectively. The signal obtained was 
amplified using a Dako Cytomation–catalyzed system 
(Dako) and visualized by DAB colorimetric reaction. 
The slides were scanned, analyzed, and quantified using 
a customized-software Microvigene (VigeneTech Inc.) 
to generate spot intensity. Each dilution curve was fitted 
with a logistic model (“Supercurve Fitting” developed 
by the Department of Bioinformatics and Computational 
Biology in MD Anderson Cancer Center) [46]. This fits a 
single curve using all the samples (i.e., dilution series) on 
a slide with the signal intensity as the response variable 
and the dilution steps as independent variables. The fitted 
curve is plotted with the signal intensities – both observed 
and fitted - on the y-axis and the log2-concentration of 
proteins on the x-axis for diagnostic purposes. The protein 
concentrations of each set of slides were then normalized 
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by median polish, which was corrected across samples by 
the linear expression values using the median expression 
levels of all antibody experiments to calculate a loading 
correction factor for each sample. The list of antibodies 
used in the RPPA analysis is shown in Supplementary 
Table S3.
RNA-Seq sample preparation and sequencing
For each cell line, total RNA was extracted by 
Direct-zol RNA kit (Zymo Research, Irvine, CA, USA). 
RNA quality was assessed by agarose gel electrophoresis 
(visual absence of significant 28S and 18S rRNA 
degradation) and by spectrophotometry. RNA-Seq 
was performed by Zymo Research facility performing 
PolyA enrichment of the RNA samples. HiSeq 2 × 50 
bp paired-end reads from RNA-Seq of a human normal-
tumor pair samples were analyzed first using the TopHat 
and Cufflinks software. TopHat (v2.0.6) was utilized for 
alignment of short reads to GRCh37, Cufflinks (v2.0.2) for 
isoform assembly and quantification, and commeRbund 
(v2.0.0) for visualization of differential analysis. Default 
parameters were used. The RNA-Seq quality control was 
performed using Dispersion, Volcano, MA, Density, PCA, 
Scatter and Box plots.
DAVID and IPA analysis
To identify the statistically significant biological 
functions and signaling pathways affected by the genes 
differentially expressed in our comparisons, we used 
Database for Annotation, Visualization and Integrated 
Discovery (DAVID) [11] and Ingenuity Pathways Analysis 
(IPA; Ingenuity Systems, Inc) [25]. IPA is the largest 
curated database and analysis system for understanding the 
signaling and metabolic pathways, molecular networks, 
and biological processes that are most significantly 
changed in a dataset of interest.
Ranking and significance of the biofunctions 
and the canonical pathways were tested by the p-value. 
Additionally, canonical pathways were ordered by the 
ratio (number of genes from the input data set that map to 
the pathway divided by the total number of molecules that 
exist in the canonical pathway).
Cell proliferation assay
Cell proliferation was measured by BrdU incorporation 
and MTT assays, as previously described [6, 47].
Western blot
Western blot was performed as previously described 
[6]. Appropriate dilutions of primary antibodies were used 
as recommended by the manufacturer.
Nude mouse xenograft model
The experimental design followed a well-established 
female nude mouse model [53]. MDA-MB-231 cells (5 × 
106 cells) mixed with Matrigel Matrix (BD Biosciences) 
were injected into the right flank of female Foxn1 nu/nu 
Balb/c athymic nude mice, aged 6–8 weeks, and allowed 
to form tumors. Tumors were measured with callipers 
every other day (length and width) and the mice weighed. 
Mice were provided with free access to food, water and 
bedding at all time and were housed with a 12 h light/
dark cycle in filter top cages containing a maximum 
of six mice per cage. Tumor volumes (mm3) were 
calculated by the formula: π/6 × width2(mm2) × length 
(mm) as previously described [53]. The experiment was 
terminated as previously described [54] in accordance 
with institutionally approved guidelines.
Ethics statement
This study was carried out in strict accordance 
with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of 
Health. The protocol was approved by the Institutional 
Ethical Commitee from the School of Medicine, 
University of Buenos Aires (ID:093/10 CD, Shool of 
Medicine).
In vivo therapy of solid tumors in mice
For MDA-MB-231 tumor xenografts, four days after 
cell injection the tumor-bearing mice were randomized 
into the following four groups (five animals per group) 
and received inhibitor treatment for 25 consecutive days.
The dose of the ACSL4 inhibitor used was 
calculated taking into account the minimal dose required 
for each individual inhibitor to produce a significant effect 
in the xenograft MDA-MB-231 model as previously 
described [4]. Unitary doses were: rosiglitazone (0.6 mg/
day) and tamoxifen (0.50 mg/day). In all cases, drugs were 
administered once a day by ip injection for rosiglitazone 
and tamoxifen was given through oral gavage during 25 
days.
Group 1 (MDA-MB-231 cell xenografts treated with 
vehicle), Group 2 (MDA-MB-231 cell xenografts treated 
with tamoxifen), Group 3 (MDA-MB- 231 cell xenografts 
treated with rosiglitazone), Group 4 (MDA-MB-231 cell 
xenografts treated with a combination of the two drugs at 
the same doses used for single-drug treatments).
Animals were maintained in pathogen-free 
conditions and procedures were performed in accordance 
with recommendations for the proper use and care of 
laboratory animals. Tumors were measured as described 




Data analysis was performed using GraphPad Prism 
Software 5.01 (La Jolla, CA, USA). Statistical significance 
was determined by analysis of variance (ANOVA) 
followed by Tukey-Kramer Multiple Comparison Test. 
Tumor response to treatment was compared using two-
way ANOVA.
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